Relationship between Wnt-1 induced secreted protein-1 expression and prognosis of breast cancer patients

doi:10.3877/cma.j.issn.1674-0807.2017.05.005

Abstract

Abstract:

Objective

To explore the relationship between the expression of Wnt-1 induced secreted protein-1(WISP-1) and the prognosis of breast cancer patients.

Methods

The specimens of breast cancer tissue and adjacent normal breast tissue were collected from 120 cases of invasive breast cancer in Third Hospital of Nanchang City from January to June 2011. The expression of WISP-1 in specimens was measured by immunohistochemical EnVision method. The clinicopathological characteristics and follow-up results were further analyzed. The relationship between WISP-1 expression in breast cancer tissue and clinicopathological characteristics was analyzed using χ² test. The survival rate was calculated with Kaplan-Meier method and the survival difference was analyzed with Log-rank test. The Cox proportional hazards model was used to analyze the prognostic factors in breast cancer patients.

Results

The positive rate of WISP-1 was 85% (102/120) in invasive breast cancer tissue, significantly higher than 35% (42/120) in normal breast tissue (χ² =7.653,P=0.003). The expression of WISP-1 was correlated with histological grade (χ²=22.846,P<0.001),lymph node metastasis(χ²=11.663,P=0.001), HER-2 expression(χ² =7.825,P=0.005) and distant metastasis(χ²=35.737,P<0.001). The follow-up time was 24.0-60.0 months, median 43.9 months. Survival analysis showed that WISP-1 expression was the prognostic factor of DFS (χ²=19.354, P<0.001). The median time to recurrence and metastasis was 48 months in patients with low expression of WISP-1, 40 months in patients with high expression of WISP-1. Cox proportional hazards model suggested that WISP-1 expression (OR=2.129,95%CI:1.099-4.124,P=0.025), age (OR=4.617,95%CI:2.803-7.605,P<0.001) and lymph node metastasis(OR=2.014,95%CI:1.209-3.355, P=0.007) were independent prognostic factors of DFS in breast cancer patients.

Conclusion

The breast cancer patients with high expression of WISP-1 have poor prognosis and WISP-1 protein can serve as an index for the prognosis of breast cancer.

Key words: Breast neoplasms, Wnt1 protein, Prognosis

Qianwen Ouyang, Jianhong Tu, Xiaobo Wu, Yali Cao, Qiuming Liu, Pinghua Hu, Wei Qu, Qiumo Lei. Relationship between Wnt-1 induced secreted protein-1 expression and prognosis of breast cancer patients[J]. Chinese Journal of Breast Disease(Electronic Edition), 2017, 11(05): 277-281.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2017.05.005

https://zhrxbzz.cma-cmc.com.cn/EN/Y2017/V11/I05/277

Figures/Tables 5

References 19

[1]	Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer[J]. Adv Exp Med Biol,2007,608:1-22.
[2]	Yeger H,Perbal B. CCN family of proteins: critical modulators of the tumor cell microenvironment.[J]. J Cell Commun Signal,2016,10(3):229-240.
[3]	Nagai Y,Watanabe M,Ishikawa S,et al. Clinical significance of Wntinduced secreted protein-1 (WISP-1/CCN4) in esophageal squamous cell carcinoma[J]. Anticancer Res,2011,31(3):991-997.
[4]	Baker R,Kent CV, Silbermann RA,et al. Pea3 transcription factors and Wnt1-induced mouse mammary neoplasia[J]. PLoS One,2010,5(1):e8854.
[5]	Holbourn KP, Acharya KR, Perbal B. The CCN family of proteins:structure-function relationships[J]. Trends Biochem Sci,2008,33(10):461-473.
[6]	Zhang H,Luo H,Hu Z,et al. Targeting WISP1 to sensitize esophageal squamous cell carcinoma to irradiation[J]. Oncotarget,2015,6(8):6218-6234.
[7]	Gurbuz I, Chiquet-Ehrismann R. CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): A focus on its role in cancer[J]. Int J Biochem Cell Biol,2015,62:142-146.
[8]	Nagai Y,Watanabe M,Ishikawa S,et al. Clinical significance of Wntinduced secreted protein-1(WISP-1/CCN4) in esophageal squamous cell carcinoma[J].Anticancer Res,2011,31(3):991-997.
[9]	Davies SR,Davies ML,Sanders A, et al. Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implications[J]. Int J Oncol,2010,36(5):1129-1136.
[10]	Shao H,Cai L,Moller M,et al. Notch1-WISP-1 axis determines the regulatory role of mesenchymal stem cell-derived stromal fibroblasts in melanoma metastasis[J]. Oncotarget,2016,7(48):79 262-79 273.
[11]	胡锐,田超,孟文建,等. Wnt-1 诱导分泌蛋白-1 在乳腺浸润性导管癌中的表达及其临床意义[J]. 四川大学学报(医学版), 2010,41(2):231-234.
[12]	Banerjee S,Sengupta K, Saxena NK, et al. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks[J]. Mol Cancer Res,2005,3(3):151-162.
[13]	Kleer CG, Zhang Y, Pan Q, et al. WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer[J]. Neoplasia,2004,6(2):179-185.
[14]	Zhang Y, Pan Q, Zhong H, et al. Inhibition of CCN6 (WISP3)expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells[J]. Breast Cancer Res,2005,7(6):1080-1089.
[15]	Daves SR,Watkins G,Mansel RE, et al. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2,and WISP-3 in human breast cancer[J]. Ann Surg Oncol,2007,14(6):1909-1918.
[16]	Yang JY, Yang MW, Huo YM, et al. High expression of WISP-1 correlates with poor prognosis in pancreatic ductal adenocarcinoma[J].Am J Transl Res,2015,7(9):1621-1628.
[17]	罗宏涛,车团结,王小虎,等. 放射治疗后血清YKL-40 变化对乳腺癌患者预后判断的价值[J/CD].中华乳腺病杂志(电子版),2016,10(4):215-219.
[18]	胡保全,胡春艳,姜军,等. 转录因子Twist 在乳腺癌中的作用及研究进展[J/CD].中华乳腺病杂志(电子版),2016,10(4):239-242.
[19]	孙子涵,潘沁汶,苑龙,等. ERβ 和PTEN 在人乳腺癌组织中的表达及其临床意义[J/CD]. 中华乳腺病杂志(电子版),2016,10(5):276-281.

变量	变量赋值
年龄	＞35岁=0,≤35岁=1
肿瘤大小	＜5cm=0,≥5cm=1
ER表达	阴性=0,阳性=1
PR表达	阴性=0,阳性=1
HER-2表达	阴性=0,阳性=1
组织学分级	1~2级=0,3级=1
淋巴结转移	无转移=0,有转移=1
脉管癌栓	无癌栓=0,有癌栓=1
WISP-1表达	低表达=0,高表达=1
有无远处转移	无转移=0,有转移=1

变量	变量赋值
年龄	＞35岁=0,≤35岁=1
肿瘤大小	＜5cm=0,≥5cm=1
ER表达	阴性=0,阳性=1
PR表达	阴性=0,阳性=1
HER-2表达	阴性=0,阳性=1
组织学分级	1~2级=0,3级=1
淋巴结转移	无转移=0,有转移=1
脉管癌栓	无癌栓=0,有癌栓=1
WISP-1表达	低表达=0,高表达=1
有无远处转移	无转移=0,有转移=1

临床病理特征	例数	WISP-1表达		χ ²值	P值
临床病理特征	例数	低表达	高表达	χ ²值	P值
年龄
≤35岁	33	13	20	0.146	0.703
＞35岁	87	31	56	0.146	0.703
肿瘤大小
＜2cm	22	6	16	3.614	0.164
≥2cm,＜5cm	90	37	53
≥5cm	8	1	7
组织学分级
1~2级	41	27	14	22.846	＜0.001
3级	79	17	62	22.846	＜0.001
淋巴结转移
无	52	28	24	11.663	0.001
有	68	16	52	11.663	0.001
ER表达
阴性	50	16	34	0.804	0.370
阳性	70	28	42	0.804	0.370
PR表达
阴性	66	27	39	1.137	0.286
阳性	54	17	37	1.137	0.286
HER-2表达
阴性	51	26	25	7.825	0.005
阳性	69	18	51	7.825	0.005
脉管癌栓
无	55	23	32	1.160	0.281
有	65	21	44	1.160	0.281
远处转移
无	41	30	11	35.737	＜0.001
有	79	14	65	35.737	＜0.001

临床病理特征	例数	WISP-1表达		χ ²值	P值
临床病理特征	例数	低表达	高表达	χ ²值	P值
年龄
≤35岁	33	13	20	0.146	0.703
＞35岁	87	31	56	0.146	0.703
肿瘤大小
＜2cm	22	6	16	3.614	0.164
≥2cm,＜5cm	90	37	53
≥5cm	8	1	7
组织学分级
1~2级	41	27	14	22.846	＜0.001
3级	79	17	62	22.846	＜0.001
淋巴结转移
无	52	28	24	11.663	0.001
有	68	16	52	11.663	0.001
ER表达
阴性	50	16	34	0.804	0.370
阳性	70	28	42	0.804	0.370
PR表达
阴性	66	27	39	1.137	0.286
阳性	54	17	37	1.137	0.286
HER-2表达
阴性	51	26	25	7.825	0.005
阳性	69	18	51	7.825	0.005
脉管癌栓
无	55	23	32	1.160	0.281
有	65	21	44	1.160	0.281
远处转移
无	41	30	11	35.737	＜0.001
有	79	14	65	35.737	＜0.001

变量	回归系数	标准误	Wald值	P值	OR值	95%置信区间
年龄	1.762	0.250	49.716	＜0.001	5.821	3.568~9.499
肿瘤大小	0.301	0.275	1.197	0.274	1.351	0.788~2.316
ER表达	-0.335	0.226	2.190	0.139	0.716	0.460~1.115
PR表达	-0.189	0.228	0.684	0.408	0.828	0.529~1.295
HER-2表达	0.364	0.232	2.463	0.117	1.439	0.913~2.267
组织学分级	0.788	0.269	8.590	0.003	2.198	1.298~3.723
淋巴结转移	1.057	0.250	17.947	＜0.001	2.879	1.765~4.696
脉管癌栓	0.303	0.232	1.706	0.191	1.354	0.859~2.132
WISP-1表达	1.165	0.296	15.547	＜0.001	3.207	1.797~5.723

Please choose a citation manager

Content to export